
    
      Patients who meet the inclusion criteria will receive Tislelizumab combined with Bevacizumab
      and albumin paclitaxel for 4 cycles. If there is no disease progression, the patient will
      continue to receive Tislelizumab maintenance therapy, until the disease progresses or death.
    
  